These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 9266528)
21. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Beal MF Biofactors; 1999; 9(2-4):261-6. PubMed ID: 10416039 [TBL] [Abstract][Full Text] [Related]
22. Serum levels of coenzyme Q10 in patients with Parkinson's disease. Jiménez-Jiménez FJ; Molina JA; de Bustos F; García-Redondo A; Gómez-Escalonilla C; Martínez-Salio A; Berbel A; Camacho A; Zurdo M; Barcenilla B; Enríquez de Salamanca R; Arenas J J Neural Transm (Vienna); 2000; 107(2):177-81. PubMed ID: 10847558 [TBL] [Abstract][Full Text] [Related]
23. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Olanow CW; Jankovic J Mov Disord; 2005; 20 Suppl 11():S3-10. PubMed ID: 15822111 [TBL] [Abstract][Full Text] [Related]
24. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Shults CW; Oakes D; Kieburtz K; Beal MF; Haas R; Plumb S; Juncos JL; Nutt J; Shoulson I; Carter J; Kompoliti K; Perlmutter JS; Reich S; Stern M; Watts RL; Kurlan R; Molho E; Harrison M; Lew M; Arch Neurol; 2002 Oct; 59(10):1541-50. PubMed ID: 12374491 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Zhu ZG; Sun MX; Zhang WL; Wang WW; Jin YM; Xie CL Neurol Sci; 2017 Feb; 38(2):215-224. PubMed ID: 27830343 [TBL] [Abstract][Full Text] [Related]
26. Neuroprotection for Parkinson's disease. LeWitt PA J Neural Transm Suppl; 2006; (71):113-22. PubMed ID: 17447422 [TBL] [Abstract][Full Text] [Related]
27. Bioenergetic approaches for neuroprotection in Parkinson's disease. Beal MF Ann Neurol; 2003; 53 Suppl 3():S39-47; discussion S47-8. PubMed ID: 12666097 [TBL] [Abstract][Full Text] [Related]
28. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. NINDS NET-PD Investigators Neurology; 2007 Jan; 68(1):20-8. PubMed ID: 17200487 [TBL] [Abstract][Full Text] [Related]
29. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Beal MF; Matthews RT Mol Aspects Med; 1997; 18 Suppl():S169-79. PubMed ID: 9266519 [TBL] [Abstract][Full Text] [Related]
30. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic. Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057 [TBL] [Abstract][Full Text] [Related]
31. Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease? Seet RC; Lim EC; Tan JJ; Quek AM; Chow AW; Chong WL; Ng MP; Ong CN; Halliwell B Antioxid Redox Signal; 2014 Jul; 21(2):211-7. PubMed ID: 24410614 [TBL] [Abstract][Full Text] [Related]
33. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Olanow CW; Schapira AH; LeWitt PA; Kieburtz K; Sauer D; Olivieri G; Pohlmann H; Hubble J Lancet Neurol; 2006 Dec; 5(12):1013-20. PubMed ID: 17110281 [TBL] [Abstract][Full Text] [Related]
34. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Elshershari H; Ozer S; Ozkutlu S; Ozme S Int J Cardiol; 2003 Mar; 88(1):101-2. PubMed ID: 12659993 [No Abstract] [Full Text] [Related]
35. Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off". Bosco D; Plastino M; Bosco F; Fava A; Rotondo A Minerva Med; 2011 Apr; 102(2):125-32. PubMed ID: 21483399 [TBL] [Abstract][Full Text] [Related]
36. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Shults CW; Beal MF; Fontaine D; Nakano K; Haas RH Neurology; 1998 Mar; 50(3):793-5. PubMed ID: 9521279 [TBL] [Abstract][Full Text] [Related]
37. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340 [TBL] [Abstract][Full Text] [Related]
38. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study. Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758 [TBL] [Abstract][Full Text] [Related]